Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients

Breast Cancer Research and Treatment

Volumn 128, Issue 3, 2011, Pages 633-641

  Naoi, Yasuto ^a   Kishi, Kazuki ^b   Tanei, Tomonori ^a   Tsunashima, Ryo ^a   Tominaga, Naoomi ^a   Baba, Yosuke ^b   Kim, Seung Jin ^a   Taguchi, Tetsuya ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

Breast cancer; DNA microarray; Hormonal therapy; Prediction of recurrence

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GOSERELIN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLASSIFIER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA MICROARRAY; GENE EXPRESSION; GENOMIC GRADE INDEX; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOLOGICAL PARAMETERS; PARTIAL MASTECTOMY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SURVIVAL; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECURRENCE; SURVIVAL ANALYSIS;

EID: 79960841940     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1145-z     Document Type: Article

References (24)

1. LJ van't Veer H Dai MJ Van de Vijver, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 10.1038/415530a (Pubitemid 34130608)
2. S Paik 2007 Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen Oncologist 12 631 635 17602054 10.1634/theoncologist.12-6-631 1:CAS:528:DC%2BD2sXosF2gs7o%3D (Pubitemid 47036199)
3. C Sotiriou P Wirapati S Loi, et al. 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 262 272 16478745 10.1093/jnci/djj052 1:CAS:528:DC%2BD28Xhs1Skt74%3D (Pubitemid 43264710)
4. K Morimoto SJ Kim T Tanei, et al. 2009 Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression Cancer Sci 100 1062 1068 19385968 10.1111/j.1349-7006.2009.01151.x 1:CAS:528:DC%2BD1MXntlSjtLg%3D
5. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
6. W Yixin GM Profjan Z Yi, et al. 2005 Gene-expression profile to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 634 635
7. DM Lance S Johanna G Joshy, et al. 2005 An expression signature for p53 status in human breast cancer predicts mutant status, transcriptional effects, and patient survival PNAS 102 13550 13555 10.1073/pnas.0506230102 (Pubitemid 41420886)
8. L Sherene D Christine HK Benjamin, et al. 2007 Definition of clinically distant molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade J Clin Oncol 25 1239 1246 10.1200/JCO.2006.07.1522 (Pubitemid 46640570)
9. D Christine P Fanny L Sherene, et al. 2007 Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicancer independent validation series Clin Cancer Res 13 3207 3214 10.1158/1078-0432.CCR-06-2765 (Pubitemid 46944903)
10. L Sherene HK Benjamin D Christine, et al. 2008 Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen BMC Genomics 9 239 10.1186/1471-2164-9-239 (Pubitemid 351804039)
11. AI Rafael H Bridget C Francois, et al. 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data Biostatistics 4 249 264 10.1093/biostatistics/4.2.249
12. JK Choi U Yu S Kim, et al. 2003 Combining multiple microarray studies and modeling interstudy variation Bioinformatics 19 Suppl 1 i84 i90 12855442 10.1093/bioinformatics/btg1010 (Pubitemid 41185603)
13. C Desmedt A Giobbie-Hurder P Neven, et al. 2009 The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial BMC Med Genomics 2 40 19573224 10.1186/1755-8794-2-40
14. B Haibe-Kains C Desmedt F Piette, et al. 2008 Comparison of prognostic gene expression signatures for breast cancer BMC Genomics 9 394 18717985 10.1186/1471-2164-9-394
15. J Stec J Wang K Coombes, et al. 2005 Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips J Mol Diagn 7 357 367 16049308 10.1016/S1525-1578(10)60565- X 1:CAS:528:DC%2BD2MXhtVWjtLnF (Pubitemid 41149651)
16. JM Bueno-de-Mesquita SC Linn R Keijzer, et al. 2009 Validation of 70-gene prognosis signature in node-negative breast cancer Breast Cancer Res Treat 117 483 495 18819002 10.1007/s10549-008-0191-2 1:STN:280:DC%2BD1MnislWmtQ%3D%3D
17. M Ishitobi TE Goranova Y Komoike, et al. 2010 Clinical utility of the 70-gene MammaPrint profile in a Japanese population Jpn J Clin Oncol 40 508 512 20110242 10.1093/jjco/hyp195
18. M Buyse S Loi L van't Veer, et al. 2006 Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 1183 1192 16954471 10.1093/jnci/djj329 1:CAS:528: DC%2BD28Xps1yjtLw%3D (Pubitemid 44390989)
19. BS Wittner DC Sgroi PD Ryan, et al. 2008 Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort Clin Cancer Res 14 2988 2993 18483364 10.1158/1078-0432.CCR-07-4723 1:CAS:528:DC%2BD1cXmtVCmtLs%3D
20. JA Sparano S Paik 2008 Development of the 21-gene assay and its application in clinical practice and clinical trials J Clin Oncol 26 721 728 18258979 10.1200/JCO.2007.15.1068 (Pubitemid 351264384)
21. EP Mamounas G Tang B Fisher, et al. 2010 Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20 J Clin Oncol 28 1677 1683 20065188 10.1200/JCO.2009.23.7610
22. KS Albain S Paik L van't Veer 2009 Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays Breast 18 Suppl 3 S141 S145 19914534 10.1016/S0960-9776(09)70290-5
23. JA Sparano 2006 TAILORx: trial assigning individualized options for treatment (Rx) Clin Breast Cancer 7 347 350 17092406 10.3816/CBC.2006.n.051 (Pubitemid 44717771)
24. JA Zujewski L Kamin 2008 Trial assessing individualized options for treatment for breast cancer: the TAILORx trial Future Oncol 4 603 610 18922117 10.2217/14796694.4.5.603 1:CAS:528:DC%2BD1cXht1Glu7fO